anti-IL1RAP CAR-T cells

anti-IL1RAP CAR-T cells are an emerging class of cellular immunotherapies engineered to target the interleukin-1 receptor accessory protein (IL1RAP), a cell surface molecule highly expressed on leukemic stem cells (LSCs) and progenitor cells in myeloid malignancies like acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Unlike many other leukemia targets, IL1RAP is typically absent on healthy hematopoietic stem cells (HSCs), providing a potential therapeutic window to eradicate the source of the cancer while sparing normal blood cell production. The therapy involves the genetic modification of T cells to express a chimeric antigen receptor (CAR) that recognizes the extracellular domain of IL1RAP, coupled with intracellular signaling domains such as CD3-zeta and co-stimulatory molecules like 4-1BB or CD28. Upon administration, these cells bind to IL1RAP-positive tumor cells, leading to localized T-cell activation, cytokine release, and direct granzyme/perforin-mediated apoptosis of the target cells. Development is currently focused on both autologous and allogeneic approaches to treat refractory hematologic cancers and potentially certain solid tumors where IL1RAP signaling drives tumor progression.

Other names

IL1RAP-CAR-T cellsIL-1RAP-CAR-T cellsIL 1RAP-CAR-T cellsAnti-IL1RAP CAR-TAnti-IL-1RAP CAR-TAnti-IL 1RAP CAR-TIL1RAP-directed CAR-T cellsIL-1RAP-directed CAR-T cellsIL 1RAP-directed CAR-T cellsAnti-IL1R3 CAR-T cellsAnti-IL-1R3 CAR-T cellsAnti-IL 1R3 CAR-T cells